INTS Intensity Therapeutics, Inc.
Company Updates ·
Cash and cash equivalents were $9.5 million at June 30, 2026. The company began activities to resume enrollment in its INVINCIBLE-3 study and restarted treatment in INVINCIBLE-4.
Cash and cash equivalents were $10.2 million at March 31, 2026. The company plans to resume enrollment in INVINCIBLE-3 at a limited number of U.S. sites by the third quarter of 2026.
Nasdaq gave Intensity until June 1, 2026 to restore a $1.00 closing bid price. The company says it may use a reverse stock split, and the notice has no immediate effect on its listing.
Nasdaq said on August 8, 2025 that Intensity meets the $2,500,000 stockholders' equity requirement. That finding rests partly on share sales made in July, and the company could still face delisting if its next periodic report does not show compliance.
Intensity sold 19,868,658 shares at an average of $0.3323 each under its at-the-market program in July 2025. The company says its cash now reaches into the second half of 2026, but the release gives no cash balance.
Nasdaq says the company, whose cash was $2,590 thousand at year-end 2024, fell short of the $2,500,000 stockholders' equity minimum and has until July 3, 2025 to submit a compliance plan.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction through direct injection of its product candidates into tumors. Its DfuseRx discovery platform creates anti-cancer product candidates that combine active agents with amphiphilic molecules, which allow the drugs to disperse through a tumor and diffuse into cancer cells. Its lead candidate, INT230-6, combines cisplatin, vinblastine sulfate and an amphiphilic molecule called SHAO in one vial at a fixed ratio. The Phase 3 INVINCIBLE-3 study tests INT230-6 as a monotherapy against standard-of-care drugs in second- and third-line treatment of certain soft tissue sarcoma subtypes, with overall survival as the endpoint. The study is a 333-patient trial. New site activations and enrollment were paused in March 2025 because of funding constraints. The Phase 2 INVINCIBLE-4 study, run with the Swiss Cancer Group, tests INT230-6 in localized triple-negative breast cancer. Full approval to resume enrollment was granted on March 26, 2026, with resumption planned for the second quarter of 2026. The company is targeting completion of enrollment by the end of 2027.
| Product or program | What it is | Stage |
|---|---|---|
| INT230-6 | Intratumoral combination of cisplatin, vinblastine sulfate and SHAO | Phase 3 INVINCIBLE-3 (enrollment paused); Phase 2 INVINCIBLE-4 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $6.8 million | $10.5 million |
| Net income (loss) | -$11.6 million | -$16.3 million |
| Cash from operations | -$9.2 million | -$15.2 million |
| Cash and equivalents | $11.9 million | $2.6 million |
Our latest story on this, dated Dec 5, 2025: "Intensity Therapeutics gets second 180 days to meet Nasdaq minimum bid price requirement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 12, 2025: "Intensity Therapeutics regains Nasdaq stockholders' equity compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 4, 2025: "Intensity Therapeutics raises $6.6 million from July 2025 at-the-market sales". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 20, 2025: "Intensity Therapeutics gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. Read the story.
Intensity Therapeutics, Inc. trades under the ticker INTS on NASDAQ.
Intensity Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Intensity Therapeutics, Inc. is 1567264. Its filings are on SEC EDGAR.
3,264,879 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Intensity Therapeutics, Inc. under United States.
Our directory classifies Intensity Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Intensity Therapeutics, Inc. is US45828J2024.
aibio.space lists Intensity Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction through direct injection of its product candidates into tumors. Its DfuseRx discovery platform creates anti-cancer product candidates that combine active agents with amphiphilic molecules, which allow the drugs to disperse through a tumor and diffuse into cancer cells.
INT230-6: Intratumoral combination of cisplatin, vinblastine sulfate and SHAO Stage: Phase 3 INVINCIBLE-3 (enrollment paused); Phase 2 INVINCIBLE-4.
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form S-1. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio